Vyome Holdings, Inc. (HIND) Fair Value 2026

HIND · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.5 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (38/100)

Quick Summary — As of 2026-08-28, Vyome Holdings, Inc. (HIND) trades at $2.21. QOC: 4.5/10. Value Trap Risk: 38/100 (LOW). 1/13 models active.

Key Facts

Ticker
HIND
Price
$2.21
Quality Score
4.5/10
Value Trap Risk
38/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 4.5/10 signals weak fundamentals

What Fair Value Does Each Model Give HIND?

1 Intrinsic Value Models vs. Current Price ($2.21)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.55 -29.9%

All Models Active

All 1 models are displayed above.

What Is Vyome Holdings, Inc. (HIND) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Vyome Holdings, Inc.'s intrinsic value is estimated at $1.55, suggesting the stock is overvalued at its current price of $2.21. With 1 out of 1 models flagging downside (-29.9% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About HIND?

1 of 13 models are currently active for HIND. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does HIND Rank in Biotechnology?

Among 625 Biotechnology stocks, HIND ranks #442 by Quality of Company score. CirclFi's QOC score of 4.5/10 evaluates 32 fundamental signals. A score of 4.5 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

As a biotech sector, Vyome Holdings, Inc. operates in a sector where partnership revenue is a critical driver of valuation. Investors evaluating HIND should weigh these sector-specific dynamics alongside our model-derived fair values.

Is HIND a Value Trap?

CirclFi's Value Trap algorithm assigns HIND a score of 38/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Vyome Holdings, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Vyome Holdings, Inc.'s fundamental quality profile registers 4.5/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HIND valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across HIND's 1 active models, average confidence is 54%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Vyome Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

EDSAEdesa Biotech, Inc.QOC 4.5ELDNEledon Pharmaceuticals, Inc.QOC 4.5MLTXMoonLake ImmunotherapeuticsQOC 4.5ENSCEnsysce Biosciences, Inc.QOC 4.5ENDVEndonovo Therapeutics, Inc.QOC 4.5BOLDBoundless Bio, Inc.QOC 4.5WINTWindtree Therapeutics, Inc.QOC 3.0CLDXCelldex Therapeutics, Inc.QOC 6.2GDTCCytoMed Therapeutics LimitedQOC 5.1EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: EDSA · ELDN · MLTX · ENSC · ENDV · BOLD · WINT · CLDX · GDTC · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to HIND?

6 companies across all industries closest to HIND’s Quality of Company score of 4.5/10.

GPOXGPO Plus, Inc.QOC 4.5STEKStemtech CorporationQOC 4.5BSPKBespoke Extracts, Inc.QOC 4.5SPWRSunPower Inc.QOC 4.5SRXHSRX Global Inc.QOC 4.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GPOX · STEK · BSPK · SPWR · SRXH · NVDA

Where Does HIND Sit in CirclFi's Biotechnology Rankings?

HIND is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Vyome Holdings, Inc.’s Valuation?

What is Vyome Holdings, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Vyome Holdings, Inc. (HIND). The Quality of Company score is 4.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HIND overvalued or undervalued right now?

At $2.21, 0 of 1 active models suggest HIND may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Vyome Holdings, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.5 mean for HIND?

Vyome Holdings, Inc.'s QOC of 4.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HIND?

CirclFi analyzes HIND with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is HIND a value trap in 2026?

Vyome Holdings, Inc.'s Value Trap score is 38/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Vyome Holdings, Inc. (HIND) a Quality of Company score of 4.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/HIND/ · Methodology
Primary sources for this HIND valuation
  • Financial statements: Vyome Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001427570) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HIND as of ; valuations recomputed .